EGIS PLC is one of the leading generic pharmaceutical manufacturers in both Hungary and Central and Eastern Europe. It is a classic pharmaceutical producer, with a full range of activity extending from generic and original research and development, through manufacture of both active ingredients and finished products, to marketing and sales.

EGIS has a total of 2,600 staff in Budapest and Körmend, while a further 1,152 professionals are employed at its subsidiaries and commercial representations both in Hungary and abroad. Approximately 90% of EGIS shares are in foreign ownership, of which 51% is held by the French drug company Servier.

65% of EGIS’s sales revenues derive from exports. The most important markets are Russia and the other CIS countries, Central and Eastern Europe, and Western Europe. 35% of sales turnover is realized in Hungary. On the basis of sales revenues, EGIS is the fifth largest pharmaceutical manufacturer and distributor, and the market leader in drug groups treating conditions of the cardiovascular and central nervous systems.

Quality assurance accompanies the entire life cycle of the product, from design through production to its appearance on the market. EGIS’s manufacturing system conforms to international GMP principles (Good Manufacturing Practice).

Registration of EGIS products in the UK is being handled by EGIS UK Ltd, a 100% owned subsidiary of EGIS PLC Hungary. Marketing of these products based on the MAs held by EGIS UK Ltd is being carried out by Medimpex UK Ltd.

Click to visit www.egis.hu